You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
McKesson
Johnson and Johnson
Colorcon
Boehringer Ingelheim

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Patent: 9,856,320

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,856,320
Title:Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
Abstract: The disclosure provides a method for immunotherapy of a cancer patient, comprises administering to the patient an Ab that inhibits signaling from the PD-1/PD-L1 signaling pathway, or a combination of such Ab and an anti-CTLA-4 Ab. This disclosure also provides a method for immunotherapy of a cancer patient comprising selecting a patient who is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the patient that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering an anti-PD-1 Ab to the selected subject. The disclosure additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
Inventor(s): Cogswell; John P. (Yardley, PA), Goldberg; Stacie M. (Potomac, MD), Gupta; Ashok Kumar (Clarksburg, MD), Jure-Kunkel; Maria (Plainsboro, NJ), Wang; Xi-Tao (Wellesley, MA), Wigginton; Jon M. (Rockville, MD)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:14/400,667
Patent Claims:see list of patent claims

Details for Patent 9,856,320

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bristol Myers Squibb YERVOY ipilimumab INJECTABLE; INJECTION 125377 001 2011-03-25   Start Trial Bristol-Myers Squibb Company (Princeton, NJ) 2032-05-15 RX Orphan search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125527 001 2015-03-04   Start Trial Bristol-Myers Squibb Company (Princeton, NJ) 2032-05-15 RX search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125527 002 2015-03-04   Start Trial Bristol-Myers Squibb Company (Princeton, NJ) 2032-05-15 RX search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125554 001 2015-11-23   Start Trial Bristol-Myers Squibb Company (Princeton, NJ) 2032-05-15 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Baxter
Colorcon
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.